ATEZOLIZUMAB + Vincristine + Irinotecan + Temozolomide for rhabdomyosarcoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 12 Mar 2021: Trial registered, NCT04796012
  2. 18 Apr 2023: Trial started, NCT04796012

The trials

NCT04796012: VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors

State
Under way
Phase
Phase 1 and Phase 2
People
23 planned
Started
18 Apr 2023
Primary completion
Jan 2027
Arms
Feasibility Cohort: Patients with relapsed or refractory solid tumors, Rhabdomyosarcoma (RMS) Cohort: Patients with rhabdomyosarcoma
Results
None posted
  1. 12 Mar 2021: Trial registered
  2. 18 Apr 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.